Data Sheet (Cat.No.T5164)

TargetMol

Cabozantinib hydrochloride

Chemical Properties



CAS No. : 1817759-42-4

Formula: C28H25ClFN3O5

Molecular Weight: 537.96

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).
Targets(IC50)	Apoptosis,FLT,c-Kit,c-Met/HGFR,ROR,TAM Receptor,VEGFR

Solubility Information

Solubility	DMSO: 5.38 mg/mL (10 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8589 mL	9.2944 mL	18.5887 mL
5 mM	0.3718 mL	1.8589 mL	3.7177 mL
10 mM	0.1859 mL	0.9294 mL	1.8589 mL
50 mM	0.0372 mL	0.1859 mL	0.3718 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011, 10(12), 2298-2308.

Torres KE, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.Clin Cancer Res. 2011 Jun 15;17(12):3943-55.

You WK, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res, 2011, 71(14), 4758-4768.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481